Epigenomics Licenses Septin 9 Biomarker To Quest For CRC LDT Development

Quest is the first commercial reference laboratory in the US to obtain a non-exclusive license to the Septin 9 biomarker from Epigenomics. Quest plans to develop a homebrew Septin 9 DNA-methylation test based on the biomarker, and market it as a supplement to colonoscopy and fecal occult blood tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories